On May 28, 2025, HC Wainwright & Co. initiated coverage on NeuroPace (NPCE, Financial), a company known for its innovative solutions in the neurological sector. The analyst behind this coverage, Yi Chen, set an initial price target of $18.00 USD, indicating a positive outlook for the company.
The current rating for NeuroPace (NPCE, Financial) is "Buy", suggesting a strong potential for investors considering this stock. This coverage comes as a fresh analysis with no prior ratings or price targets to influence the newly established "Buy" rating.
This initiation and positive rating by HC Wainwright & Co. could serve as an important indicator for market participants interested in investing in NeuroPace (NPCE, Financial). Keep an eye on NeuroPace (NPCE) for potential developments and performance reflecting this new analyst coverage.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for NeuroPace Inc (NPCE, Financial) is $17.17 with a high estimate of $20.00 and a low estimate of $15.00. The average target implies an upside of 35.60% from the current price of $12.66. More detailed estimate data can be found on the NeuroPace Inc (NPCE) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, NeuroPace Inc's (NPCE, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for NeuroPace Inc (NPCE, Financial) in one year is $8.89, suggesting a downside of 29.78% from the current price of $12.66. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the NeuroPace Inc (NPCE) Summary page.
